ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib1

The ataxia telangiectasia mutated (ATM) protein kinase plays a central role in the cellular response to DNA damage. Loss or inactivation of both copies of the ATM gene (ATM) leads to ataxia telangiectasia, a devastating childhood condition characterized by neurodegeneration, immune deficiencies, and cancer predisposition. ATM is also absent in approximately 40% of mantle cell lymphomas (MCLs), and we previously showed that MCL cell lines with loss of ATM are sensitive to poly-ADP ribose polymerase (PARP) inhibitors. Next-generation sequencing of patient tumors has revealed that ATM is altered in many human cancers including colorectal, lung, prostate, and breast. Here, we show that the colorectal cancer cell line SK-CO-1 lacks detectable ATM protein expression and is sensitive to the PARP inhibitor olaparib. Similarly, HCT116 colorectal cancer cells with shRNA depletion of ATM are sensitive to olaparib, and depletion of p53 enhances this sensitivity. Moreover, HCT116 cells are sensitive to olaparib in combination with the ATM inhibitor KU55933, and sensitivity is enhanced by deletion of p53. Together our studies suggest that PARP inhibitors may have potential for treating colorectal cancer with ATM dysfunction and/or colorectal cancer with mutation of p53 when combined with an ATM kinase inhibitor.

[1]  D. Lobo,et al.  Are DNA repair factors promising biomarkers for personalized therapy in gastric cancer? , 2013, Antioxidants & redox signaling.

[2]  Wei Yuan,et al.  DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. , 2015, The New England journal of medicine.

[3]  Y. Shiloh,et al.  Ataxia-telangiectasia (A-T): An emerging dimension of premature ageing , 2017, Ageing Research Reviews.

[4]  T. Stankovic,et al.  ATM Mutations in Sporadic Lymphoid Tumours , 2002, Leukemia & lymphoma.

[5]  K. Kuča,et al.  The development of ataxia telangiectasia mutated kinase inhibitors. , 2014, Mini reviews in medicinal chemistry.

[6]  D. Stoppa-Lyonnet.  The biological effects and clinical implications of BRCA mutations: where do we go from here? , 2016, European Journal of Human Genetics.

[7]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[8]  Melanie A. Huntley,et al.  Recurrent R-spondin fusions in colon cancer , 2012, Nature.

[9]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[10]  S. Lees-Miller,et al.  Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines , 2014, Cell cycle.

[11]  M. Dyer,et al.  The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. , 2010, Blood.

[12]  Joon-Oh Park,et al.  Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Thomas Helleday,et al.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase , 2005, Nature.

[14]  Alan Ashworth,et al.  Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. , 2006, Cancer research.

[15]  J. Boultwood.  Ataxia telangiectasia gene mutations in leukaemia and lymphoma , 2001, Journal of clinical pathology.

[16]  Y. Shiloh.  ATM: expanding roles as a chief guardian of genome stability. , 2014, Experimental cell research.

[17]  W. Kim,et al.  Mutation at Intronic Repeats of the Ataxia-Telangiectasia Mutated (ATM) Gene and ATM Protein Loss in Primary Gastric Cancer with Microsatellite Instability , 2013, PloS one.

[18]  K. Hemminki,et al.  Mutations and polymorphisms in TP53 gene--an overview on the role in colorectal cancer. , 2012, Mutagenesis.

[19]  K. Khanna,et al.  The Plant Isoflavenoid Genistein Activates p53 and Chk2 in an ATM-dependent Manner* , 2001, The Journal of Biological Chemistry.

[20]  L. Klampfer,et al.  K-Ras, intestinal homeostasis and colon cancer. , 2015, Current clinical pharmacology.

[21]  L. Staudt,et al.  Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[22]  Y Taya,et al.  DNA damage induces phosphorylation of the amino terminus of p53. , 1997, Genes & development.

[23]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[24]  N. Curtin,et al.  Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM , 2004, Cancer Research.

[25]  B. McKay,et al.  Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53 , 2012, EMBO molecular medicine.

[26]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[27]  T. Kipps,et al.  ATM Mutations in Cancer: Therapeutic Implications , 2016, Molecular Cancer Therapeutics.

[28]  T. Paull.  Mechanisms of ATM Activation. , 2015, Annual review of biochemistry.

[29]  R. Guy,et al.  Optimization of a Novel Series of Ataxia-Telangiectasia Mutated Kinase Inhibitors as Potential Radiosensitizing Agents. , 2016, Journal of medicinal chemistry.

[30]  M. Kastan,et al.  DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation , 2003, Nature.

[31]  A. Ryan,et al.  ATM and ATR as therapeutic targets in cancer. , 2015, Pharmacology & therapeutics.

[32]  M. O’Connor,et al.  ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors , 2010, Molecular Cancer Therapeutics.

[33]  Vladimir Vacic,et al.  Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions , 2014, Genome Biology.

[34]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[35]  K. Kinzler,et al.  Requirement for p53 and p21 to sustain G2 arrest after DNA damage. , 1998, Science.

[36]  S. Chandna,et al.  ATM kinase: Much more than a DNA damage responsive protein. , 2016, DNA repair.

[37]  E. Kohn,et al.  PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.